Dogwood Therapeutics Inc. Ordinary Shares DWTX 深 滬
已收盤 07-25 16:00:00 美东时间
4.77
+0.040
+0.85%
華盛通- 最 高4.89
- 今 開4.80
- 成交量 1.05万股
- 最 低 4.75
- 昨 收 4.73
- 總市值 911.59万
- 52周最高 29.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.62
- 委 比 99.15%
- 總股本 191.11万
- 歷史最高 417.75
- 量 比 0.65
- 振 幅 2.96%
- 歷史最低 1.87
- 每 手 1
- 風險率 2.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dogwood Therapeutics Approves CFO Salary Increase
Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On June 27, 2025...
07-03 04:28
Dogwood Therapeutics Approves Equity Plan Amendment
Dogwood Therapeutics ( ($DWTX) ) just unveiled an announcement. On June 18, 202...
06-24 22:49
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Sidoti Events, LLC, an affilia...
06-10 19:30
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Dogwood Therapeutics的首席执行官Greg Duncan将在2025年6月11日至12日的Sidoti Small-Cap Virtual Conference上进行公司概述，包括其Halneuron和其他产品线的最新进展。会议时间为美国东部时间6月11日上午9:15，可在此注册：https://sidoti.zoom.us/webinar/register/WN_C6ACWY1kTXGa0eBkFbVd0w。此会议还包括与Duncan的一对一会谈安排。Dogwood专注于开发治疗疼痛和疲劳相关疾病的新型药物。其Halneuron是一种非阿片类镇痛剂，而IMC-1和IMC-2则为抗病毒药物，针对包括纤维肌痛和长新冠在内的疾病。Halneuron的II期临床试验数据预计于2025年底公布。请注意，Dogwood的候选药物尚未被证明有效。如需更多信息，请访问www.dwtx.com。
06-03 13:15
Virios Therapeutics Non-GAAP EPS of -$8.45
Virios Therapeutics press release (NASDAQ:DWTX): Q1 Non-GAAP EPS of -$8.45. Cash on hand of $17.5M provides operational runway through Q1 2026. More on Virios Therapeutics Dogwood Therapeutics announc...
05-08 22:23
Dogwood Therapeutics Q1 EPS $(8.45) Misses $(2.38) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.45) per share which missed the analyst consensus estimate of $(2.38) by 255.04 percent. This is a 402.98 percent decrease over losses of $(1.68) per
05-08 21:04
美股大行评级 | 潜在涨幅38%！花旗：首予通用汽车(GM)"买入"评级，目标价62美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1122085978711785472.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Devon Energy(DVN)"超配"评级，目标价从54美元升至56美元</p> <p>• HC Wainwright & Co.：上调Dogwood Therapeutics(
04-24 09:56
Dogwood Therapeutics Regains Nasdaq Compliance
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has
04-11 21:16
Dogwood Therapeutics regains compliance with Nasdaq
Dogwood Therapeutics (NASDAQ:DWTX) said it has regained compliance with the minimum stockholders’ equity requirement. “The company has a strong cash position of $17.5 million as of the end of Q1, with...
04-03 21:08
